GQG:ASXGQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh Analysis
Data as of 2026-03-16 - not real-time
A$1.69
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
GQG Partners trades at AUD 1.69, well below its DCF‑derived fair value of 1.96, implying roughly a 14½% upside. The stock’s P/E of 7.35 is dramatically lower than the industry average of 16.49, and it offers a hefty 12.09% dividend yield with a payout ratio near 79% backed by strong operating cash flow and minimal leverage. Recent earnings beat, a rise in funds under management to US$172.9 bn and notable insider buying have driven a 4% price rally, while technicals remain neutral – the 20‑day SMA sits just above price and the MACD is slightly bearish but volume is increasing.
Given the combination of a sizable valuation gap, robust cash generation, and a resilient dividend, the stock appears undervalued and defensible. However, high 30‑day volatility (~50%) and a modest beta suggest price swings may be pronounced, so investors should weigh the upside against short‑term market noise.
Given the combination of a sizable valuation gap, robust cash generation, and a resilient dividend, the stock appears undervalued and defensible. However, high 30‑day volatility (~50%) and a modest beta suggest price swings may be pronounced, so investors should weigh the upside against short‑term market noise.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Significant valuation upside vs DCF fair value
- Strong dividend yield with sustainable payout
- Recent earnings beat and insider buying boosting sentiment
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Continued growth in funds under management
- Robust cash flow supporting dividend and reinvestment
- Undervalued relative to peers and industry averages
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Stable cash generation and low leverage
- Potential for dividend adjustments if earnings plateau
- Exposure to asset‑management sector cycles and regulatory changes
Key Metrics & Analysis
Financial Health
Revenue Growth2.00%
Profit Margin57.32%
P/E Ratio7.3
ROE107.64%
ROA81.28%
Debt/Equity6.04
P/B Ratio7.9
Op. Cash FlowA$483.1M
Free Cash FlowA$388.3M
Industry P/E16.5
Technical Analysis
TrendNeutral
RSI42.3
SupportA$1.64
ResistanceA$1.97
MA 20A$1.79
MA 50A$1.71
MA 200A$1.80
MACDBearish
VolumeIncreasing
Fear & Greed Index79.45
Valuation
Fair ValueA$1.96
Target PriceA$1.94
Upside/Downside14.50%
GradeUndervalued
TypeValue
Dividend Yield12.09%
Risk Assessment
Beta0.33
Volatility49.64%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.